Atlas Trials

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

Clinical trial NCT01585272 · COMPLETED

Trial details

NCT number
NCT01585272
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Alzheimer's Dementia
Start date
2012-08-01
Primary completion
2015-06-01
Enrollment
121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.